Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.92USD
26 May 2017
Change (% chg)

$-0.61 (-0.48%)
Prev Close
$127.53
Open
$127.23
Day's High
$127.67
Day's Low
$126.83
Volume
1,093,155
Avg. Vol
2,027,737
52-wk High
$129.00
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Janssen Biotech submits application for approval of sirukumab in U.S. for rheumatoid arthritis
Friday, 23 Sep 2016 08:00am EDT 

Janssen Biotech Inc:Janssen submits application seeking approval of sirukumab in United States for rheumatoid arthritis.  Full Article

J&J wins dismissal of New Jersey lawsuits over talc claims - Bloomberg
Friday, 2 Sep 2016 04:04pm EDT 

:J&J wins dismissal of New Jersey lawsuits over talc claims - Bloomberg.  Full Article

Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 10:31am EDT 

Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16.  Full Article

Genmab to receive $15 mln in milestone payments from Janssen
Wednesday, 17 Aug 2016 03:40pm EDT 

Genmab A/S : Genmab announces submission of Supplemental Biologics License Application to FDA for daratumumab in relapsed multiple myeloma .Genmab to receive USD 15 million in milestone payments from Janssen.  Full Article

Janssen submits application to U.S. FDA to expand indication for daratumumab
Wednesday, 17 Aug 2016 03:25pm EDT 

Janssen Biotech Inc : Janssen submits application to u.s. Fda to expand indication for daratumumab (darzalex®) . Application seeks second indication for daratumumab in combination with standard of care regimens for patients with multiple myeloma .Has also submitted a request for priority review of sbla for daratumumab.  Full Article

Johnson & Johnson announces ruling related to Remicade
Wednesday, 17 Aug 2016 01:54pm EDT 

Johnson & Johnson : Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing . Janssen is also continuing appeal process in proceedings related to 471 patent before U.S. Patent & Trademark office . Commercial launch of an infliximab biosimilar prior to outcome of appeals would be considered an at-risk launch .Reaffirms its sales guidance for operational sales growth for FY 2016 of 3 pct to 4 pct, notwithstanding possibility of a biosimilar launch on or after Oct. 3, 2016.  Full Article

Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research
Tuesday, 26 Jul 2016 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer .Myers squibb co - phase 2 clinical trial will evaluate tolerability and clinical activity of combination of these agents in nsclc patients.  Full Article

Janssen says Health Canada approves Imbruvica for treatment of chronic lymphocytic leukemia
Wednesday, 20 Jul 2016 08:00am EDT 

Johnson & Johnson :Health Canada approves Imbruvica® (ibrutinib) for first-line treatment of chronic lymphocytic leukemia.  Full Article

Health Canada approves INVOKAMET for treatment of adults with type 2 diabetes
Wednesday, 20 Jul 2016 07:00am EDT 

Johnson & Johnson :Health Canada approves INVOKAMET for treatment of adults with type 2 diabetes.  Full Article

Ionis Pharmaceuticals licenses oral antisense drug to Janssen
Tuesday, 19 Jul 2016 07:00am EDT 

Ionis Pharmaceuticals Inc : Ionis Pharmaceuticals licenses first oral antisense drug acting locally in the GI tract to Janssen . Under terms of agreement, which covers three programs, Ionis is eligible to receive nearly $800 million in milestone payments . Will receive tiered royalties that on average are double-digits on sales from product that is successfully commercialized .Earned $10 million from Janssen Biotech Inc (Janssen) upon licensing IONIS-JBI1-2.5(Rx).  Full Article

More From Around the Web

J&J's Ethicon hit with $2.16 million verdict in vaginal-mesh case

A state court jury in Philadelphia on Friday ordered Johnson & Johnson to pay $2.16 million to a Pennsylvania woman who claimed she suffered injuries due to pelvic mesh devices manufactured by the company's Ethicon unit.